GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
02 2019
Historique:
received: 13 03 2018
accepted: 10 08 2018
revised: 07 08 2018
pubmed: 6 9 2018
medline: 27 2 2019
entrez: 6 9 2018
Statut: ppublish

Résumé

The ETS family transcription factor GABPA is suggested as an oncogenic element, which is further supported by the recent reporting of it as the sole ETS member to activate the mutant TERT promoter in thyroid carcinomas (TC). However, it remains unclear how GABPA contributes to TC pathogenesis. The present study is designed to address this issue. TERT expression was significantly diminished in TERT promoter-mutated TC cells upon GABPA inhibition. Surprisingly, GABPA depletion led to robustly increased cellular invasion independently of TERT promoter mutations and TERT expression. DICER1, a component of the microRNA machinery, was identified as a downstream effector of GABPA. GABPA facilitated Dicer1 transcription while its depletion reduced Dicer1 expression. The mutation of the GABPA binding site in the DICER1 promoter led to diminished basal levels of DICER1 promoter activity and abolishment of GABPA-stimulated promoter activity as well. The forced DICER1 expression abrogated the invasiveness of GABPA-depleted TC cells. Consistently, the analyses of 93 patients with papillary thyroid carcinoma (PTC) revealed a positive correlation between GABPA and DICER1 expression. GABPA expression was negatively associated with TERT expression and promoter mutations, in contrast to published observations in cancer cell lines. Lower GABPA expression was associated with distant metastasis and shorter overall/disease-free survival in PTC patients. Similar results were obtained for PTC cases in the TCGA dataset. In addition, a positive correlation between GABPA and DICER1 expression was seen in multiple types of malignancies. Taken together, despite its stimulatory effect on the mutant TERT promoter and telomerase activation, GABPA may itself act as a tumor suppressor rather than an oncogenic factor to inhibit invasion/metastasis in TCs and be a useful predictor for patient outcomes.

Identifiants

pubmed: 30181547
doi: 10.1038/s41388-018-0483-x
pii: 10.1038/s41388-018-0483-x
doi:

Substances chimiques

GA-Binding Protein Transcription Factor 0
GABPA protein, human 0
Tumor Suppressor Proteins 0
TERT protein, human EC 2.7.7.49
Telomerase EC 2.7.7.49
DICER1 protein, human EC 3.1.26.3
Ribonuclease III EC 3.1.26.3
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

965-979

Références

BMC Cancer. 2017 May 26;17(1):380
pubmed: 28549418
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Endocr Relat Cancer. 2017 May;24(5):209-220
pubmed: 28235956
Nat Rev Cancer. 2017 Jun;17(6):337-351
pubmed: 28450705
Mol Biol Cell. 2013 Dec;24(23):3634-50
pubmed: 24109597
J Clin Oncol. 2015 Feb 20;33(6):667-8
pubmed: 25605839
Nat Rev Endocrinol. 2016 Nov;12(11):646-653
pubmed: 27418023
Oncogene. 2011 Mar 17;30(11):1302-17
pubmed: 21057533
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Endocr Relat Cancer. 2016 Mar;23(3):R143-55
pubmed: 26733501
Cell. 2010 Jun 25;141(7):1195-207
pubmed: 20603000
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2312-7
pubmed: 23345428
FASEB J. 2013 Nov;27(11):4375-83
pubmed: 23884427
Curr Pharm Des. 2014;20(41):6386-403
pubmed: 24975608
Front Genet. 2016 May 09;7:83
pubmed: 27242892
Nat Rev Endocrinol. 2011 Mar 29;7(7):420-30
pubmed: 21448143
Oncogene. 2016 Aug 18;35(33):4312-20
pubmed: 26725326
Oncogene. 2018 Jun;37(25):3369-3383
pubmed: 29353884
Oncogene. 2013 Apr 25;32(17):2131-9
pubmed: 22689055
Genes Dev. 2009 Dec 1;23(23):2700-4
pubmed: 19903759
Cancer. 2016 May 1;122(9):1370-9
pubmed: 26969876
J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6
pubmed: 23833040
Cancer Res. 2017 May 1;77(9):2534-2547
pubmed: 28209613
Genes Dev. 2015 Nov 1;29(21):2219-24
pubmed: 26515115
Nat Commun. 2014 Oct 29;5:5203
pubmed: 25351418
Nat Commun. 2013;4:2185
pubmed: 23887589
J Clin Endocrinol Metab. 2013 Mar;98(3):956-7
pubmed: 23472230
Oncogene. 2017 Oct 26;36(43):5927-5938
pubmed: 28650464
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Cancer Lett. 2018 Oct 10;434:33-41
pubmed: 30017965
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Clin Oncol. 2014 Sep 1;32(25):2718-26
pubmed: 25024077
J Mol Endocrinol. 2017 Feb;58(2):R129-R146
pubmed: 28057768
Oncogene. 2013 Sep 5;32(36):4203-13
pubmed: 23045275
Oncogene. 2014 Oct 16;33(42):4978-84
pubmed: 24141777
PLoS One. 2012;7(12):e49892
pubmed: 23284628
Genes (Basel). 2016 Jul 18;7(7):
pubmed: 27438857
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907
pubmed: 28323937
Nat Commun. 2014 Oct 29;5:5202
pubmed: 25351346
Nucleic Acids Res. 2014 Jun;42(10):6256-69
pubmed: 24753418
Thyroid. 2007 Apr;17(4):289-301
pubmed: 17465858
Thyroid. 2016 Jul;26(7):901-10
pubmed: 27184112
J Clin Invest. 2017 Jun 1;127(6):2159-2175
pubmed: 28436938
Science. 2015 May 29;348(6238):1036-9
pubmed: 25977370
Cancer. 2014 Oct 1;120(19):2965-79
pubmed: 24898513

Auteurs

Xiaotian Yuan (X)

Reproductive Center, Shandong University, Jinan, 250013, PR China.
Department of Medicine-Solna, Karolinska Institutet, Karolinska University Hospital CMM, SE-171 76, Stockholm, Sweden.

Ninni Mu (N)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden.

Na Wang (N)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden.

Klas Strååt (K)

Department of Medicine-Solna, Karolinska Institutet, Karolinska University Hospital CMM, SE-171 76, Stockholm, Sweden.

Anastasios Sofiadis (A)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden.

Yanxia Guo (Y)

Department of Medicine-Solna, Karolinska Institutet, Karolinska University Hospital CMM, SE-171 76, Stockholm, Sweden.
Central Research Laboratory, Shandong University Second Hospital, Jinan, 250033, PR China.

Adam Stenman (A)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden.

Kailin Li (K)

Central Research Laboratory, Shandong University Second Hospital, Jinan, 250033, PR China.

Guanghui Cheng (G)

Central Research Laboratory, Shandong University Second Hospital, Jinan, 250033, PR China.

Lu Zhang (L)

Central Research Laboratory, Shandong University Second Hospital, Jinan, 250033, PR China.

Feng Kong (F)

Central Research Laboratory, Shandong University Second Hospital, Jinan, 250033, PR China.

Lars Ekblad (L)

Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.

Johan Wennerberg (J)

Division of Oto-rhino-laryngology, Head and Neck Surgery, Department of Clinical Sciences Lund, Skåne University Hospital, Lund University, Lund, Sweden.

Inga-Lena Nilsson (IL)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.

C Christofer Juhlin (CC)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden.

Catharina Larsson (C)

Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital CCK, SE-171 76, Stockholm, Sweden. Catharina.Larsson@ki.se.

Dawei Xu (D)

Department of Medicine-Solna, Karolinska Institutet, Karolinska University Hospital CMM, SE-171 76, Stockholm, Sweden. Dawei.Xu@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH